A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Purpose
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.
Condition
- Metabolic Dysfunction-Associated Steatotic Liver Disease
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Have liver fat content ≥8% - Have ELF score of ≥9 and ≤10.8 at screening - Have VCTE LSM ≥10 kilopascal (kPa) and <20 kPa at screening
Exclusion Criteria
- Have any other type of liver disease other than MASLD - Have a body mass index (BMI) <25 kilogram per square meter (kg/m2) - Prior decompensated liver disease (history of esophageal/gastric varices, ascites, hepatic encephalopathy) - Have lost more than 11 pounds within the 3 months prior to screening - Have a hemoglobin A1c (HbA1c) greater than 10% - Have type 1 diabetes
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Single (Participant)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Tirzepatide (TZ01) |
Participants will receive tirzepatide subcutaneously (SC) |
|
|
Placebo Comparator Placebo (TZ01) |
Participants will receive placebo SC |
|
|
Experimental Retatrutide (RT01) |
Participants will receive retatrutide SC |
|
|
Placebo Comparator Placebo (RT01) |
Participants will receive placebo SC |
|
Recruiting Locations
Chandler 5289282, Arizona 5551752 85224
Gilbert 5295903, Arizona 5551752 85297
Peoria 5308480, Arizona 5551752 85381
Sun City 5316201, Arizona 5551752 85351
Tucson 5318313, Arizona 5551752 85712
Fountain Valley 5350207, California 5332921 92708
714-988-2021
Fresno 5350937, California 5332921 93720
559-970-3441
Long Beach 5367929, California 5332921 90815
562-997-1000
Clermont 4151352, Florida 4155751 34711
407-426-9299
Daytona Beach 4152872, Florida 4155751 32114
Delray Beach 4153132, Florida 4155751 33484
401-773-7855
Fort Myers 4155995, Florida 4155751 33907
239-931-3368
Inverness 4159786, Florida 4155751 34452
352-341-2100
Jacksonville 4160021, Florida 4155751 32256
904-680-0871
Jupiter 4160610, Florida 4155751 33458
Lady Lake 4161118, Florida 4155751 32159
352-500-5252
Lakewood Rch 7255365, Florida 4155751 34211
941-727-7772
Miami 4164138, Florida 4155751 33122-1722
786-706-1216
Miami Lakes 4164186, Florida 4155751 33016-1518
305-330-9977
Orlando 4167147, Florida 4155751 32803
Orlando 4167147, Florida 4155751 32806
407-705-3471
Port Orange 4169156, Florida 4155751 32127
386-304-7070
St. Petersburg 4171563, Florida 4155751 33710
877-791-0656
Tamarac 4174738, Florida 4155751 33321
877-791-0656
Indianapolis 4259418, Indiana 4921868 46202
317-278-1652
South Bend 4926563, Indiana 4921868 46635
574-904-9617
West Des Moines 4881346, Iowa 4862182 50266
515-329-6800
Bastrop 4315535, Louisiana 4331987 71220
318-281-6040
New Iberia 4334971, Louisiana 4331987 70560
813-851-0135
Shreveport 4341513, Louisiana 4331987 71105
318-525-3227
New Bedford 4945121, Massachusetts 6254926 02740
Southfield 5010636, Michigan 5001836 48075
248-864-5242
Las Vegas 5506956, Nevada 5509151 89109
702-680-1500
Pennington 5102535, New Jersey 5101760 08534
215-676-6696
Warren Township 8299577, New Jersey 5101760 07059
New York 5128581, New York 5128638 10036
Yonkers 5145215, New York 5128638 10701
Morehead City 4480153, North Carolina 4482348 28557
252-499-8623
Akron 5145476, Ohio 5165418 44320
Westlake 5176517, Ohio 5165418 44145
440-363-4000
Providence 5224151, Rhode Island 5224323 02905
Austin 4671654, Texas 4736286 78745
512-649-0082
Bellaire 4673353, Texas 4736286 77401
281-844-3160
Brownsville 4676740, Texas 4736286 78526
Denison 4685892, Texas 4736286 75020
469-819-0228
Farmers Branch 4690198, Texas 4736286 75234
214-347-7577
Houston 4699066, Texas 4736286 77004
Houston 4699066, Texas 4736286 77054
877-791-0656
Houston 4699066, Texas 4736286 77079
281-809-3234
Houston 4699066, Texas 4736286 77084
281-944-3610
Houston 4699066, Texas 4736286 77089
281-944-3610
McAllen 4709796, Texas 4736286 78503
281-944-3610
Pasadena 4717782, Texas 4736286 77505
832-847-1727
San Antonio 4726206, Texas 4736286 78229
210-949-0122
San Antonio 4726206, Texas 4736286 78229
210-692-7157
Shavano Park 4728147, Texas 4736286 78231
210-545-4900
Sugar Land 4734825, Texas 4736286 77478
Wylie 4743275, Texas 4736286 75098
469-449-3645
Ogden 5779206, Utah 5549030 84403
801-614-0010
Sandy City 5781061, Utah 5549030 84070
801-409-2040
Guaynabo 4565119, Puerto Rico 00968
7874045252
More Details
- Status
- Recruiting
- Sponsor
- Eli Lilly and Company
Study Contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or1-317-615-4559
LillyTrials@Lilly.com